Skip to Content

Heron Therapeutics Inc HRTX

Morningstar Rating
$3.20 −0.05 (1.54%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

HRTX is trading within a range we consider fairly valued.
Price
$3.23
Fair Value
$5.33
Uncertainty
Very High
1-Star Price
$4.49
5-Star Price
$5.83
Economic Moat
Hwf
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HRTX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$3.25
Day Range
$3.183.32
52-Week Range
$0.503.93
Bid/Ask
$3.19 / $3.20
Market Cap
$482.09 Mil
Volume/Avg
4.8 Mil / 2.4 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
3.60
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
126

Comparables

Valuation

Metric
HRTX
IMVT
SLRN
Price/Earnings (Normalized)
Price/Book Value
6.591.00
Price/Sales
3.60
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
HRTX
IMVT
SLRN
Quick Ratio
1.8213.1813.08
Current Ratio
2.4713.7013.27
Interest Coverage
Quick Ratio
HRTX
IMVT
SLRN

Profitability

Metric
HRTX
IMVT
SLRN
Return on Assets (Normalized)
−23.83%−44.70%−28.15%
Return on Equity (Normalized)
−49.06%−35.30%
Return on Invested Capital (Normalized)
−36.87%−53.44%−41.97%
Return on Assets
HRTX
IMVT
SLRN
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
RqtmlpgndNlgy$589.6 Bil
Vertex Pharmaceuticals Inc
VRTX
HlzjkblzfFmgyhpc$126.9 Bil
Regeneron Pharmaceuticals Inc
REGN
WrdwjgdMtqvj$117.2 Bil
Moderna Inc
MRNA
BxfcwjhhdQffk$46.4 Bil
Alnylam Pharmaceuticals Inc
ALNY
KpddnksgbFpsbgmv$30.1 Bil
argenx SE ADR
ARGX
GjbwtfjtKtyd$28.0 Bil
BioNTech SE ADR
BNTX
KhgknqjdJld$20.6 Bil
Biomarin Pharmaceutical Inc
BMRN
DzhqbzctnRzkwpf$16.0 Bil
United Therapeutics Corp
UTHR
GsknkdprkXcn$14.6 Bil
Incyte Corp
INCY
HbtjnrqccWbsytfy$13.0 Bil

Sponsor Center